Testing antibodies to predict heart muscle disease progression
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with dilated cardiomyopathy (a heart muscle condition).
- You do not have a serious infection that is not responding to treatment.
- You are not currently experiencing uncontrolled bleeding.
- You are not pregnant or breastfeeding.
- You are willing and able to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This study looks at people who have been newly diagnosed with heart failure to find rare forms of heart muscle disease (cardiomyopathy) early and start the right treatment. It uses advanced heart imaging (CMR) and requires that you have not had heart problems before.
This study is a registry for people with dilated cardiomyopathy (DCM)—a condition where the heart's main pumping chamber becomes enlarged and weak. It aims to learn more about DCM, especially in people from different ethnic backgrounds, by collecting health information over time.
This study follows people with a specific genetic change in the BAG3 gene that causes dilated cardiomyopathy (DCM), a condition where the heart muscle is weakened. It aims to understand the natural course of the disease over time.
This trial tests whether heart muscle cells made from stem cells, injected into the heart, can improve heart function in people with heart failure and a weak heart pump. It may be an option for those who are not getting enough help from other treatments.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.